Imeros (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. By stabilizing the neuronal membrane, it temporarily halts nerve impulse transmission, resulting in loss of sensation in the area supplied by the blocked nerves.

The specific dose of Imeros is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical judgment. Dosage calculations follow established guidelines for local anesthetic administration, and the prescriber sets the exact amount to be injected.

Safety data for mepivacaine during pregnancy and lactation are limited. It is classified as a Category C or unknown, meaning it should only be used when the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both mepivacaine and lidocaine are amide‑type local anesthetics, but mepivacaine has a slightly longer duration of action and a lower pKa, which may result in faster onset in mildly acidic tissues. Lidocaine is more widely used and has a broader safety profile, while mepivacaine may be preferred when a longer block is desired without vasoconstrictor addition.

Imeros should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture and freezing. Ensure the vial or ampoule remains intact and discard any solution that appears discolored or contains particles.

Imeros is supplied as a sterile injectable solution for infiltration or perineural injection. The clinician injects the solution directly into the tissue or around the target nerve under aseptic conditions, using appropriate needles and techniques to achieve the desired anesthetic block.

Serious adverse events, though rare, include allergic reactions such as anaphylaxis, cardiovascular toxicity like arrhythmias or cardiac arrest, central nervous system toxicity leading to seizures, and prolonged or profound nerve block. Immediate medical attention is required if any of these symptoms occur.

Imeros is contraindicated in patients with a known hypersensitivity to mepivacaine, other amide‑type local anesthetics, or any component of the formulation. It should also be avoided in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those receiving interacting medications that increase the risk of toxicity.